Skip to main content

Advertisement

SpringerLink
Log in

Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab

  • Case Report
  • Published:
Oral and Maxillofacial Surgery Aims and scope Submit manuscript

Abstract

Background

Osteonecrosis of the jaw (ONJ) is defined by areas of tissue breakdown and exposure of bone in the maxillofacial region that fail to heal within 8 weeks after identification by a health provider in a patient who has not received radiation of the jaws. The disease affects the quality of life and produces significant morbidity in afflicted patients. ONJ is correlated with such risk factors as treatment with bisphosphonates, dental extraction-related trauma, chemotherapy, corticosteroids, renal osteodystrophy and infections. Although the use of bisphosphonates is associated with osteonecrosis of the jaw, the pathophysiology of bisphosphonate-associated ONJ is still unknown. It has been assumed that bisphosphonates lead to the inhibition of capillary angiogenesis and disturbances in the activities of both osteoblasts and osteoclasts, thereby impairing bone remodelling. Currently, inhibitors of angiogenesis used in the treatment of cancer patients are implicated in isolated cases of ONJ.

Case report

This manuscript reports a case of ONJ in a female patient who received bevacizumab (Avastin®, Roche), a humanised monoclonal antibody that recognises and blocks vascular endothelial growth factor (VEGF)-A.

Conclusion

The anti-angiogenic agent, bevacizumab, may increase the risk of osteonecrosis of the jaw. This agent inhibits VEGF and, therefore, also presumably represses the vascularisation of the jaw, which leads to healing complications. Due to increasing use of bevacizumab, patients receiving this agent should be closely monitored for possible side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, Arlen PM, Wright JJ, Parnes H, Figg WD, Dahut WL (2009) Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 27:221–226

    Article  PubMed  CAS  Google Scholar 

  2. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117

    Article  PubMed  Google Scholar 

  3. Disel U, Beşen AA, Özyilkan Ö, Er E, Canpolat T (2012) A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culpit. Oral Oncol 48:e2–e3

    Article  PubMed  Google Scholar 

  4. Ngamphaiboon N, Frustino JL, Kossoff EB, Sulllivan MA, O’Connor TL (2011) Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab. Clin Breast Cancer 11:252–257

    Article  PubMed  CAS  Google Scholar 

  5. Hoefert S, Eufinger H (2010) Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110:463–469

    Article  PubMed  Google Scholar 

  6. Hopp RN, Pucci J, Santos-Silva AR, Jorge J (2012) Osteonecrosis after administration of intravitreous bevacizumab. J Oral Maxillofac Surg 70:632–635

    Article  PubMed  Google Scholar 

  7. Guarneri V, Miles D, Robert N, Dieras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P (2010) Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 122:181–188

    Article  PubMed  CAS  Google Scholar 

  8. Marx RE, Tursun R (2012) Suppurative osteomyelitis bisphosphonate induced osteonecrosis, osteoradionecrosis: a blinded histopathologic comparison and its implications for the mechanism of each disease. Int J Oral Maxillofac Surg 41:283–289

    Article  PubMed  CAS  Google Scholar 

  9. Sanna G, Preda L, Bruschini R, Cossu Rocca M, Ferretti S, Adamoli L, Verri E, Franceschelli L, Goldhirsch A, Nolè F (2006) Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol 17:1512–1516

    Article  PubMed  CAS  Google Scholar 

  10. Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Stürzenbaum S, Pautke C (2012) Bisphosphonate-related osteonecrosis of the jaws—characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg 40:303–309

    Article  PubMed  Google Scholar 

  11. Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, Visvikis A, Nikolakopoulou A, Acholos V, Karapanagiotidis G, Batziou E, Skarlos DV (2009) Combination of bisphosphonate and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76:209–211

    Article  PubMed  CAS  Google Scholar 

  12. Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G, Huryn JM (2008) Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 26:4037–4038

    Article  PubMed  Google Scholar 

  13. Traina TT, Norton L, Drucker K, Singh B (2006) Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer. Oncologist 11:1070–1071

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ruhr-University Bochum, Bochum, Germany

    Daria Pakosch, Dimitrios Papadimas, Johanna Munding, Darafsch Kawa & Marcus Stephan Kriwalsky

Authors
  1. Daria Pakosch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dimitrios Papadimas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Johanna Munding
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Darafsch Kawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marcus Stephan Kriwalsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcus Stephan Kriwalsky.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pakosch, D., Papadimas, D., Munding, J. et al. Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab. Oral Maxillofac Surg 17, 303–306 (2013). https://doi.org/10.1007/s10006-012-0379-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10006-012-0379-9

Keywords

Search

Navigation